Browsing Pharmacology & Therapeutics (Scholarly Publications) by Subject "Alzheimer's disease"
Now showing items 1-8 of 8
-
Aß Facilitates LTD at Schaffer Collateral Synapses Preferentially in the Left Hippocampus
(2018)Promotion of long-term depression (LTD) mechanisms by synaptotoxic soluble oligomers of amyloid-β (Aß) has been proposed to underlie synaptic dysfunction in Alzheimer’s disease (AD). Previously, LTD was induced by relatively ... -
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity
(Oxford University Press, 2008)Non-steroidal anti-inflammatory agents (NSAIDs) are associated with a marked reduction in the risk of developing Alzheimer's disease, a form of dementia characterized by the accumulation of amyloid plaques containing the ... -
Exosomes neutralize synaptic-plasticity-disrupting activity of Aß assemblies in vivo.
(2013)Abstract BACKGROUND: Exosomes, small extracellular vesicles of endosomal origin, have been suggested to be involved in both the metabolism and aggregation of Alzheimer's disease (AD)-associated amyloid β-protein (Aβ). ... -
GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo
(2010)Currently, treatment with the relatively low-affinity NMDA receptor antagonist memantine provides limited benefit in Alzheimer's disease (AD). One probable dose-limiting factor in the use of memantine is the inhibition of ... -
Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances
(2012)The cognitive and related symptoms of Alzheimer's disease are mainly attributable to synaptic failure. Here we review recent research on how the Alzheimer's disease amyloid ?-protein (A?) affects glutamate receptors and ... -
Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aß in vivo.
(2014)Many endogenous factors influence the time course and extent of the detrimental effects of amyloid β-protein (Aβ) on synaptic function. Here, we assessed the impact of varying endogenous glutamatergic and cholinergic ... -
Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aß synaptotoxicity
(2014)Alzheimer's disease (AD) is associated with pathological assembly states of amyloid-β protein (Aβ). Aβ-related synaptotoxicity can be blocked by anti-prion protein (PrP) antibodies, potentially allowing therapeutic targeting ... -
Secreted amyloid ß-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity
(2014)Evidence for a central role of amyloid β-protein (Aβ) in the genesis of Alzheimer’s disease (AD) has led to advanced human trials of Aβ-lowering agents. The “amyloid hypothesis” of AD postulates deleterious effects of ...